Asthma is a common, chronic disease usually characterized by airway inflammation,
affecting 1–18% of the population worldwide (Initiative, 2020). Airway inflammation is …

Background Although inhaled corticosteroid (ICS) medication is considered the cornerstone
treatment for patients with persistent asthma, few ICS pharmacogenomic studies have …

There is wide variability in the response to inhaled corticosteroids (ICS) in asthma. While
some of this heterogeneity of response is due to adherence and environmental causes …

Background Inhaled corticosteroids (ICSs) are considered the most effective anti-
inflammatory therapy for asthma control and management; however, there is substantial …

Rationale Substantial variability in response to asthma treatment with inhaled corticosteroids
(ICS) has been described among individuals and populations, suggesting the contribution of …

To the Editor, Inhaled corticosteroids (ICS) improve asthma control in most, but not all
patients. 1, 2 Currently, biomarkers that help clinicians to pre‐dict individual ICS …

Background Pharmacogenetics studies of anti‐inflammatory medication of asthma have
expanded rapidly in recent decades, but the clinical value of their findings remains limited …

Background Inhaled corticosteroid (ICS) response among patients with asthma is influenced
by genetics, but biologically actionable insights based on associations have not been found …

Bronchial asthma is a common inflammatory disease caused by a combination of genetic
and environmental factors. To discover the genes and cellular pathways underlying asthma …

While genome-wide association studies have identified genes involved in differential
treatment responses to inhaled corticosteroids (ICS) in asthma, few studies have evaluated …